Hoth Therapeutics Gains Crucial Approval for Cancer Treatment in Spain with Promising Trial Results#Spain#Madrid#Hoth_Therapeutics#HT-001#EGFR_Inhibitor
Hoth Therapeutics Gains Crucial Approval for Cancer Treatment in Spain with Promising Trial Results
Hoth Therapeutics announces Spanish approval of its HT-001 clinical trial, showcasing promising efficacy for cancer patients experiencing skin toxicities.
third-news.com
May 5, 2026 at 8:28 PM
Hoth Therapeutics Gains Crucial Approval for Cancer Treatment in Spain with Promising Trial Results#Spain#Madrid#Hoth_Therapeutics#HT-001#EGFR_Inhibitor
J INTS BIO Unveils Promising Results for JIN-A02, a Fourth-Generation EGFR Inhibitor#South_Korea#Seoul#J_INTS_BIO#EGFR_Inhibitor#JIN-A02
J INTS BIO Unveils Promising Results for JIN-A02, a Fourth-Generation EGFR Inhibitor
J INTS BIO has revealed groundbreaking clinical research on JIN-A02, a fourth-generation EGFR inhibitor, offering new hope for patients with lung cancer.
third-news.com
February 12, 2026 at 7:06 AM
J INTS BIO Unveils Promising Results for JIN-A02, a Fourth-Generation EGFR Inhibitor#South_Korea#Seoul#J_INTS_BIO#EGFR_Inhibitor#JIN-A02
Abbisko Therapeutics Unveils Groundbreaking Cancer Research at AACR 2026#USA#San_Diego#EGFR_Inhibitor#Abbisko_Therapeutics#pan-KRAS_Inhibitor
Abbisko Therapeutics Unveils Groundbreaking Cancer Research at AACR 2026
Abbisko Therapeutics showcased six key preclinical cancer research findings at AACR 2026, highlighting advancements in pan-KRAS and other targeted therapies.
third-news.com
April 23, 2026 at 3:52 AM
Abbisko Therapeutics Unveils Groundbreaking Cancer Research at AACR 2026#USA#San_Diego#EGFR_Inhibitor#Abbisko_Therapeutics#pan-KRAS_Inhibitor
Eilean Therapeutics Unveils Groundbreaking Pan-EGFR Inhibitor for NSCLC Treatment at Major Cancer Conference#United_States#Dover#EGFR_Inhibitor#Eilean_Therapeutics#ZE77-0273
Eilean Therapeutics Unveils Groundbreaking Pan-EGFR Inhibitor for NSCLC Treatment at Major Cancer Conference
Eilean Therapeutics showcases their innovative pan-EGFR inhibitor, ZE77-0273, at the AACR-NCI-EORTC conference, highlighting its promise in non-small cell lung cancer treatment.
third-news.com
October 13, 2025 at 8:29 PM
Eilean Therapeutics Unveils Groundbreaking Pan-EGFR Inhibitor for NSCLC Treatment at Major Cancer Conference#United_States#Dover#EGFR_Inhibitor#Eilean_Therapeutics#ZE77-0273
Hoth Therapeutics Unveils Promising Results for HT-001 Targeting EGFR Inhibitor-Associated Skin Eruptions#USA#New_York#Hoth_Therapeutics#HT-001#EGFR_Inhibitor
Hoth Therapeutics Unveils Promising Results for HT-001 Targeting EGFR Inhibitor-Associated Skin Eruptions
Hoth Therapeutics announces impressive findings for HT-001, a potential breakthrough in treating skin eruptions from EGFR inhibitors, to be revealed at AAD 2025.
third-news.com
March 5, 2025 at 6:52 PM
Hoth Therapeutics Unveils Promising Results for HT-001 Targeting EGFR Inhibitor-Associated Skin Eruptions#USA#New_York#Hoth_Therapeutics#HT-001#EGFR_Inhibitor